Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and TQB2450 with Chemotherapy in Advanced Biliary Tract Cancer
NCT05812430Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Apr 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib, benmelstobart in biliary tract cancer (BTC), sponsored by The First Affiliated Hospital of Zhengzhou University. Status: unknown.
02
Drugs
anlotinibbenmelstobart
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05812430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05812430.